Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
Open Access
- 26 June 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 105 (3), 613-620
- https://doi.org/10.1007/s11060-011-0629-y
Abstract
Approximately one-third of patients with advanced, HER2-positive breast cancer develop brain metastases. A significant proportion of women experience central nervous system (CNS) progression after standard radiation therapy. The optimal treatment in the refractory setting is undefined. This study evaluated the toxicity and efficacy of lapatinib in combination with chemotherapy among patients with HER2-positive, progressive brain metastases. Patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and cranial radiotherapy were included. The primary endpoint was CNS objective response, defined as a ≥50% volumetric reduction of CNS lesion(s) in the absence of new or progressive CNS or non-CNS lesions, or increasing steroid requirements. The study was closed early after 22 of a planned 110 patients were enrolled due to excess toxicity and lack of efficacy in the lapatinib plus topotecan arm. The objective response rate (ORR) in the lapatinib plus capecitabine arm was 38% (exact 95% confidence interval [CI] 13.9–68.4). No responses were observed in the lapatinib plus topotecan arm. Although the study was stopped prior to full enrollment, some promising indications of CNS activity were noted for lapatinib plus capecitabine. The combination of lapatinib plus topotecan was not active and was associated with excess toxicity.This publication has 21 references indexed in Scilit:
- Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabineAnnals of Oncology, 2010
- Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experienceBritish Journal of Cancer, 2010
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast CancerClinical Cancer Research, 2009
- Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial DataClinical Cancer Research, 2008
- Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the BrainJNCI Journal of the National Cancer Institute, 2008
- Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survivalJournal of Neuro-Oncology, 2008
- Survival in patients with brain metastases from breast cancerCancer, 2008
- Capecitabine Therapy of Central Nervous System Metastases from Breast CancerJournal of Neuro-Oncology, 2007
- Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinomaCancer, 2006
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003